Immune Thrombocytopenic Purpura

Hematology·MeSH: Purpura, Thrombocytopenic, Idiopathic

9 drugs in development·6 companies·3 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Promacta	Royalty Pharma plc (RPRX)

Phase 3(5)

Drug	Company
hbm9161 dose a	Q BioMed Inc. (QBIO)
hbm9161 dose b	Q BioMed Inc. (QBIO)
mezagitamab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
mezagitamab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
prn1008	Principia Biopharma Inc. (PRNB)

Phase 1/Phase 2(3)

Drug	Company
biological	MOMENTA PHARMACEUTICALS INC (MNTA)
intravenous immunoglobulin	MOMENTA PHARMACEUTICALS INC (MNTA)
m254	MOMENTA PHARMACEUTICALS INC (MNTA)

BioSniper tracks 9 drugs in development for Immune Thrombocytopenic Purpura across 6 companies.

There are 3 clinical trials targeting Immune Thrombocytopenic Purpura tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.